United States, 24th Mar 2025 – With rising concerns surrounding Bird Flu, the ongoing cold and flu season, and the long-term effects of COVID-19, Dr. Michael Scoma, a Yale Hospital-trained, board-certified infectious disease specialist, is making himself available as a trusted resource for media and public health discussions.
As misinformation continues to cloud public understanding of infectious diseases, Dr. Scoma is stepping forward to provide expert analysis and guidance on pressing health issues, including:
Dr. Scoma has built a reputation as one of New York City’s most sought-after infectious disease experts, offering both inpatient and outpatient care at his offices in Manhattan and Long Island. His expertise spans a wide range of conditions, including Lyme disease, post-COVID complications, and complex immunological disorders.
"At a time when public health information is often muddled, I want to provide the public with clear, science-based insights that empower individuals to make informed decisions about their health," said Dr. Scoma.
Dr. Scoma is available for live interviews, expert panels, and rapid-response media inquiries. His in-depth knowledge, combined with a commitment to compassionate care, has earned him recognition from both patients and peers in the medical field.
For media inquiries, interviews, or expert commentary, please contact:
Contact: William Schleisner
Email: drscomapress@gmail.com
Phone: 646-820-6758
Website: michaelrscomamd.com
About Dr. Michael Scoma, MD
Dr. Michael Scoma is a board-certified infectious disease specialist trained at Yale New Haven Hospital. He leads a distinguished practice in New York City, specializing in infectious diseases, post-viral syndromes, and complex immunological disorders. Dr. Scoma is dedicated to providing individualized, evidence-based care while contributing to public health discussions through media and professional engagements.
Organization: Dr. Michael Scoma MD
Contact Person: William Schleisner
Website: https://michaelrscomamd.com/
Email: Send Email
Country:United States
Release id:25649
Disclaimer: The views, recommendations, and opinions expressed in this content belong solely to the third-party experts. This site was not involved in the writing and production of this article.